Pelareorep Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Pelareorep comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Multiple Myeloma. Most recent publication: Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects., J Hematol Oncol, 2025.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.Dona AA, Tandoh T, Nigam L, et al. · J Hematol Oncol · 2025
Publications by year
2025–2025: 1 publications.
2025
1
Publications by indication
Multiple Myeloma (1)
- Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.
Publications by journal
- J Hematol Oncol1 paper
All Pelareorep publications (1)
2025 (1 paper)
- Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.Dona AA, Tandoh T, Nigam L, et al. · J Hematol Oncol · 2025 · Derived
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Thu, 14 May 2026 22:10:22 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).